Literature DB >> 22079149

Glycan-modifying bacteria-derived soluble factors from Bacteroides thetaiotaomicron and Lactobacillus casei inhibit rotavirus infection in human intestinal cells.

Svetlana Varyukhina1, Miguel Freitas, Sabine Bardin, Emilie Robillard, Emmanuelle Tavan, Catherine Sapin, Jean-Pierre Grill, Germain Trugnan.   

Abstract

Rotaviruses attach to intestinal cells in a process that requires glycan recognition. Some bacteria from the gut microflora have been shown to modify cell-surface glycans. In this study, human intestinal cultured cells were incubated with bacteria-derived soluble factors and infected with rotavirus. Results show that only bacterial soluble factors that increase cell-surface galactose namely, those of Bacteroides thetaiotaomicron and Lactobacillus casei were able to efficiently block rotavirus infections. Increasing cell-surface galactose using galactosyltransferase resulted in a similar blockage of rotavirus infections. These results indicate that manipulation of cell-surface intestinal glycans by bacterial soluble factors can prevent rotavirus infection in a species-specific manner, and should now be considered a potential therapeutic approach against rotavirus infection.
Copyright © 2011 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22079149     DOI: 10.1016/j.micinf.2011.10.007

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  30 in total

1.  Viruses and the Microbiota.

Authors:  Christopher M Robinson; Julie K Pfeiffer
Journal:  Annu Rev Virol       Date:  2014       Impact factor: 10.431

Review 2.  Pathogen-induced secretory diarrhea and its prevention.

Authors:  S Anand; S Mandal; P Patil; S K Tomar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-29       Impact factor: 3.267

3.  Bacterial lipopolysaccharide binding enhances virion stability and promotes environmental fitness of an enteric virus.

Authors:  Christopher M Robinson; Palmy R Jesudhasan; Julie K Pfeiffer
Journal:  Cell Host Microbe       Date:  2014-01-15       Impact factor: 21.023

4.  Microbiota-Dependent Priming of Antiviral Intestinal Immunity in Drosophila.

Authors:  Christine L Sansone; Jonathan Cohen; Ari Yasunaga; Jie Xu; Greg Osborn; Harry Subramanian; Beth Gold; Nicolas Buchon; Sara Cherry
Journal:  Cell Host Microbe       Date:  2015-11-11       Impact factor: 21.023

5.  A combination of scGOS/lcFOS with Bifidobacterium breve M-16V protects suckling rats from rotavirus gastroenteritis.

Authors:  M Rigo-Adrover; S Saldaña-Ruíz; K van Limpt; K Knipping; J Garssen; J Knol; A Franch; M Castell; F J Pérez-Cano
Journal:  Eur J Nutr       Date:  2016-04-25       Impact factor: 5.614

Review 6.  Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents.

Authors:  Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

7.  Transkingdom Interactions Important for the Pathogenesis of Human Viruses.

Authors:  Andrew Nishimoto; Nicholas Wohlgemuth; Jason Rosch; Stacey Schultz-Cherry; Valerie Cortez; Hannah M Rowe
Journal:  J Infect Dis       Date:  2021-06-16       Impact factor: 5.226

Review 8.  Intestinal Microbiota-A Promising Target for Antiviral Therapy?

Authors:  Mengling Yang; Yang Yang; Qingnan He; Ping Zhu; Mengqi Liu; Jiahao Xu; Mingyi Zhao
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

Review 9.  Viral interactions with the host and microbiota in the intestine.

Authors:  Clara Moon; Thaddeus S Stappenbeck
Journal:  Curr Opin Immunol       Date:  2012-05-22       Impact factor: 7.486

10.  Disruption of the human gut microbiota following Norovirus infection.

Authors:  Adam M Nelson; Seth T Walk; Stefan Taube; Mami Taniuchi; Eric R Houpt; Christiane E Wobus; Vincent B Young
Journal:  PLoS One       Date:  2012-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.